SURFACTANT THERAPY IN PRETERM INFANTS

早产儿的表面活性剂治疗

• 批准号: 6307748
• 负责人: SUSAN SCOTT
• 金额: $ 2.24万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6307748
• 关键词: blood pressure; bronchopulmonary dysplasia; cardiac output; clinical research; cortisol; epidermal growth factor; heart rate; human subject; human therapy evaluation; medical complication; outcomes research; premature infant human; pulmonary surfactants; respiratory airway volume; respiratory distress syndrome of newborn; respiratory function; ultrasound blood flow measurement

We hypothesize that infants with RDS and who respond poorly to surfactant therapy without acute improvement in pulmonary function (studied by tidal volume, compliance and oxygen saturations) or hemodynamics (Doppler-derived cardiac output, blood pressure heart rate) are at greater risk for development of severe BPD, and that this will correlate with low levels of EGF and cortisol. Biostatistician, Informatics ONLY.

我们假设患有RDS的婴儿和对表面活性剂治疗反应不佳而肺功能（通过潮气量、顺应性和氧饱和度研究）或血流动力学（多普勒衍生的心输出量、血压和心率）没有急性改善的婴儿发生严重BPD的风险更大，这与低水平的EGF和皮质醇相关。 生物统计学家，仅信息学。